| NCT ID | NCT02884375 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Condition | Hematologic Malignancies |
| Study Type | OBSERVATIONAL |
| Enrollment | 3,000 participants |
| Start Date | 2010-09 |
| Primary Completion | 2027-11 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 3,000 participants in total. It began in 2010-09 with a primary completion date of 2027-11.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The management of older patients with cancer has become a major public health concern in Western countries because of the aging of the population and steady increase in cancer incidence with advancing age. Cancer treatment of aged patients is complex due to comorbidities, polypharmacy and functional status. The heterogeneity of the older population in terms of comorbidities and functional status may explain the difficulty in establishing management recommendations. Study hypothesis is that a geriatric consultation using Geriatric Assessment (GA) can evaluate patient's resource and strengths, in order to help oncologist to define the most effective treatment. The GA developed by geriatricians and recommended by the International Society of Geriatric Oncology (SIOG), is a multidimensional assessment of general health status; comorbidities; functional status; nutritional, cognitive, psychological, and social parameters; and medications. The GA uses validated geriatric scales to produce an inventory of problems, which can then serve to develop an individualized geriatric intervention plan; it may be an important step in selecting elderly patients for cancer screening and treatment. The objectives are: * To assess the role of GA for decision making process for older patients with cancer * To identify geriatric and oncologic factors associated with overall survival, treatment feasibility, toxicities, morbidities * To develop and/or validate screening tests for frailty in geriatric oncology * To develop and validate frailty classifications Method: The ELCAPA (ELderly CAncer PAtient) survey is a French multicentric prospective study that includes all patients age 70 years or older who has a diagnosis of solid cancer or hematologic malignancies in French hospitals
Eligibility Criteria
Inclusion Criteria: * Patient aged 70 years or older * Diagnosed cancer at all stage * Referred to a geriatrician for GA * Given oral non-opposition from patient or a legally mandated person Exclusion Criteria: * Oral opposition
Contact & Investigator
PHILIPPE CAILLET, MD
PRINCIPAL INVESTIGATOR
Assistance Publique - Hôpitaux de Paris
Frequently Asked Questions
Who can join the NCT02884375 clinical trial?
This trial is open to participants of all sexes, aged 70 Years or older, studying Hematologic Malignancies. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT02884375 currently recruiting?
Yes, NCT02884375 is actively recruiting participants. Contact the research team at philippe.caillet@aphp.fr for enrollment information.
Where is the NCT02884375 trial being conducted?
This trial is being conducted at Créteil, France.
Who is sponsoring the NCT02884375 clinical trial?
NCT02884375 is sponsored by Assistance Publique - Hôpitaux de Paris. The principal investigator is PHILIPPE CAILLET, MD at Assistance Publique - Hôpitaux de Paris. The trial plans to enroll 3,000 participants.